News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ChemoCentryx, Inc. Cancels IPO



11/16/2008 1:16:09 AM

PeHUB -- ChemoCentryx Inc., a Mountain View, Calif.-based developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has withdrawn registration for a $57.5 million IPO, citing “market conditions.” The company had planned to trade on the Nasdaq, with Credit Suisse serving as lead underwriter.

Read at Private Equity Hub
Read at Forbes


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES